Skip to main content
Contact Us
Subscribe
E-Edition
39°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Omeros Corporation - Common Stock
(NQ:
OMER
)
9.180
+0.060 (+0.66%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Omeros Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
44 Biggest Movers From Yesterday
October 05, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm
October 04, 2021
From
The Schall Law Firm
Via
Business Wire
Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher
October 04, 2021
Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation – OMER
October 04, 2021
From
Rosen Law Firm
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
October 04, 2021
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5...
Via
Benzinga
Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump
October 04, 2021
Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
30 Stocks Moving In Monday's Mid-Day Session
October 04, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021
October 04, 2021
Upgrades According to Raymond James, the prior rating for Roper Technologies Inc (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 04, 2021
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 30.07% to $3.59 during Monday's pre-market session. The market value of their outstanding shares is at $137.3...
Via
Benzinga
54 Biggest Movers From Friday
October 04, 2021
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....
Via
Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Exposures
Product Safety
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher
October 01, 2021
Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Stocks Mixed as Investors Try to Brush Off Economic Anxieties
October 01, 2021
The Dow Jones Industrial Average is up 204 points at midday, after trading sideways this morning as September's anxieties over inflation and slowing economic growth continue to grip Wall Street.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
October 01, 2021
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume...
Via
Benzinga
Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet
October 01, 2021
Midway through trading Friday, the Dow traded up 0.88% to 34,141.74 while the NASDAQ rose 0.12% to 14,465.49. The S&P also rose, gaining 0.58% to 4,332.44. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Here's Why Omeros Stock Is Tanking Today
October 01, 2021
The narsoplimab program hasn't proceeded as swimmingly as investors thought.
Via
The Motley Fool
Why Are Omeros Shares Plunging On Friday?
October 01, 2021
The FDA has identified deficiencies regarding Omeros Corporation's (NASDAQ: OMER) marketing application of narsoplimab for hematopoietic stem cell transplant-associated...
Via
Benzinga
Exposures
Product Safety
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September
October 01, 2021
Following the market opening Friday, the Dow traded up 0.49% to 34,010.27 while the NASDAQ fell 0.23% to 14,415.00. The S&P also rose, gaining 0.16% to 4,314.50. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 01, 2021
From
Omeros Corporation
Via
Business Wire
Why Omeros Stock Is Plummeting This Week
September 30, 2021
The biotech stock was part of a larger Wall Street sell-off.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Looking Into Omeros's Return On Capital Employed
September 20, 2021
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $...
Via
Benzinga
Omeros: Q2 Earnings Insights
August 09, 2021
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to...
Via
Benzinga
Omeros Corporation Reports Second Quarter 2021 Financial Results
August 09, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
August 03, 2021
From
Omeros Corporation
Via
Business Wire
Return On Capital Employed Overview: Omeros
June 24, 2021
Omeros (NASDAQ:OMER) reported Q1 sales of $21.06 million. Earnings fell to a loss of $30.61 million, resulting in a 9.47% decrease from last quarter. In Q4, Omeros brought in $10....
Via
Benzinga
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients
June 14, 2021
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of...
Via
Benzinga
Earnings Scheduled For August 9, 2021
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
June 14, 2021
From
Omeros Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.